Champions Oncology, Inc. splits its revenue into 5 lines in its filings. The largest line in fiscal 2026, which ended Apr 30, 2026 was Pharmacology Services at $57.1 million, 96% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2027
Jul 31, 2026
|
FY 2026
Apr 30, 2026
|
FY 2025
Apr 30, 2025
|
FY 2024
Apr 30, 2024
|
FY 2023
Apr 30, 2023
|
FY 2022
Apr 30, 2022
|
FY 2021
Apr 30, 2021
|
FY 2020
Apr 30, 2020
|
FY 2019
Apr 30, 2019
|
FY 2018
Apr 30, 2018
|
FY 2017
Apr 30, 2017
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
61
|
59
|
57
|
50
|
54
|
49
|
41
|
32
|
27
|
—
|
—
|
| Pharmacology Services |
58
+19.1%
share 95.7%
|
57
+17.6%
share 96.1%
|
49
+3.3%
share 85.3%
|
47
-7.2%
share 93.8%
|
51
+8.3%
share 94.1%
|
47
+18.6%
share 95.4%
|
39
share 96.2%
|
—
|
—
|
—
|
—
|
| Other Services |
—
|
—
|
—
|
—
|
—
|
2
+59.0%
share 4.5%
|
1
share 3.4%
|
—
|
—
|
—
|
—
|
| Product And Service Other |
1
-60.0%
share 2.1%
|
2
-58.5%
share 2.6%
|
4
+18.7%
share 6.5%
|
3
+1.8%
share 6.2%
|
3
share 5.7%
|
—
|
—
|
—
|
—
|
—
|
—
|
| Translational Oncology Solutions TOS License Revenue |
1
share 2.2%
|
1
-83.7%
share 1.3%
|
5
share 8.2%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Personalized Oncology Services |
—
|
—
|
—
|
0
-84.5%
share 0.0%
|
0
+136.7%
share 0.2%
|
0
-70.5%
share 0.1%
|
0
share 0.4%
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CSBR (Nasdaq)
- Fiscal year ends
- April 30
- Incorporated in
- DE
- Headquarters
- Baltimore, MD
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 771856
- Former names
- CHAMPIONS BIOTECHNOLOGY, INC. (until Mar 30, 2011); CHAMPIONS SPORTS INC (until Feb 16, 2007)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.